Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NGM831 |
| Trade Name | |
| Synonyms | NGM-831|NGM 831 |
| Drug Descriptions |
NGM831 is a humanized antibody that targets ILT3 and prevents the interaction of ILT3 with its ligands fibronectin and ApoE, potentially resulting in enhanced antitumor immune response (Cancer Res 2022;82(12_Suppl):Abstract nr LB216). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C186492 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| NGM831 | NGM831 | 0 | 1 |
| NGM831 + Pembrolizumab | NGM831 Pembrolizumab | 0 | 1 |